Mikaela Naylon Give Kids a Chance Act of 2025
Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Mikaela Naylon Give Kids a Chance Act of 2025
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.
Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.
The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.
The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2030. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.
GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
- Introduced in Senate Formatted Text PDF Formatted XML
- AKIN GUMP STRAUSS HAUER & FELD
- AKIN GUMP STRAUSS HAUER & FELD
- GLAUKOS CORPORATION
- TWENTY-FIRST CENTURY GROUP, INC.
- AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
- GLAUKOS CORPORATION
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Centers For Disease Control & Prevention (CDC)
- Centers For Medicare and Medicaid Services (CMS)
- Food & Drug Administration (FDA)
- Health & Human Services, Dept of (HHS)
- Natl Institutes of Health (NIH)
Cite this page
U.S. Congress. (2026). S. 3302: Mikaela Naylon Give Kids a Chance Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-S-3302/
"S. 3302: Mikaela Naylon Give Kids a Chance Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-3302/.
S. 3302, 119th Cong. (2026), https://openamerica.io/bill/119-S-3302/.
[S. 3302: Mikaela Naylon Give Kids a Chance Act of 2025](https://openamerica.io/bill/119-S-3302/)